All
Maintenance Lynparza Tablets Approved in Ovarian Cancer
August 17th 2017Lynparza tablets (olaparib) tablets were granted FDA approval as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
The Surprising Link Between Cancer Caregiver Burden and Patient Self Image
August 17th 2017This disconnect can lead to increased burden for caregivers. Researchers from City of Hope National Medical Center in Duarte, California, found that patients view themselves as being more able than their caregivers thought.
A Promising New Agent for Epithelial Ovarian Cancer
August 15th 2017A new agent showed a favorable toxicity profile for patients with epithelial ovarian cancer. The drug, mirvetuximab soravtansine (IMGN853), also demonstrated encouraging clinical activity in a phase 1 trial presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Exciting Advances Are Coming for First-line CML Treatment
August 10th 2017Kendra Sweet, M.D., discussed the various factors that must be taken into account when prescribing first-line therapies to patients with CML, the novel studies that are paving the way for improved outcomes in patients, and the increasing likelihood for TKI discontinuation on the horizon.
Expert Discusses Stem Cell Research and Personalizing Lung Cancer Care
August 9th 2017During an interview with CURE, Desai, an assistant professor of medicine at Stanford Medicine, shared insight on his research in stem cells and why discovering which cells have the potential to form lung cancer is significant to the treatment paradigm.